President Trump has exposed the dirty secret of drug pricing: There is a shadowy third player in the transaction between patients and their pharmacists: middlemen who have taken a big kickback from the drug manufacturer, which may or may not be reflected in patients' out-of-pocket costs.
It's time to stop defending a system that is clearly in dire need of reform, stop issuing reports and setting up new roadblocks, and start providing Americans with prescription drugs that are both safe and affordable.
We at HHS are working with President Trump on a comprehensive plan to bring down the high price of prescription drugs.
Because Genentech is a leading developer of cancer therapies, some doctors also fear that the company's pricing plans for Avastin - around $8,800 a month - may encourage other companies to charge more for their own oncology drugs.
While American taxes pay for much of the research and development that goes into creating the new, life-saving drugs, American consumers continue to subsidize the cost of the drugs for consumers across the world.
To get discounts on some drugs, private insurers are willing to pay top prices for blockbuster pharmaceuticals like Vioxx, despite the fact that Vioxx was rumored to cause fatal strokes and heart attacks.
The rising cost of prescription drugs has sparked a prairie fire that is spreading across our nation.
To drive down high drug costs, we need to shine a light on the negotiations between drug manufacturers, middleman negotiators and pharmacies.
With the skyrocketing costs of prescription drugs, American taxpayers shouldn't be footing the bill for medicine going to waste.
I think we can build broad bipartisan support for bringing down prescription drug costs.
We have taken on the health insurance industry, we have taken on the drug companies, instituting programs to lower the cost of prescription drugs.
The reason prescription drugs are so important at the state level is because they're eating up the Medicaid budget.
